Personalized neoantigen vaccines: A new approach to cancer immunotherapy |
| |
Authors: | Amanda R. Aldous Jesse Z. Dong |
| |
Affiliation: | Neon Therapeutics, Cambridge, MA 02139, USA |
| |
Abstract: | Neoantigens arise from somatic mutations that differ from wild-type antigens and are specific to each individual patient, which provide tumor specific targets for developing personalized cancer vaccines. Decades of work has increasingly shown the potential of targeting neoantigens to generate effective clinical responses. Current clinical trials using neoantigen targeting cancer vaccines, including in combination with checkpoint blockade monoclonal antibodies, have demonstrated potent T-cell responses against those neoantigens accompanied by antitumor effects in patients. Personalized neoantigen vaccines represent a potential new class of cancer immunotherapy. |
| |
Keywords: | Peptide Vaccine Neoantigen Personalized |
本文献已被 ScienceDirect 等数据库收录! |